Carlos
Perez-Rizquez
,
Alba
Rodriguez-Otero
and
Jose M.
Palomo
*
Department of Biocatalysis, Institute of Catalysis (CSIC), Marie Curie 2, Cantoblanco, Campus UAM, 28049 Madrid, Spain. E-mail: josempalomo@icp.csic.es; Fax: +34-91-585-4760
First published on 4th July 2019
This review describes the recent advances in the design of novel artificial metalloenzymes and their application in C–H activation reactions. The combination of enzymes and metal or organometallic complexes for the creation of new artificial metalloenzymes has represented a very exciting research line. In particular, the development of proteins with the ability to perform C–H functionalization presents a significant challenge. Here we discuss the development of these processes on natural metalloenzymes by using directed evolution, biotin-(strept)avidin technologies, photocatalytic hybrids or reconstitution of heme-protein technology.
Different approaches have been described for the preparation of artificial metalloenzymes (Fig. 2).9 Mainly, we have emphasized three different strategies: (I) creation of metalloenzymes with new catalytic activities or improved activity from a natural one. A directed evolution technique to modify the metal-coordinated amino acid environment in natural metalloenzymes has been applied to produce enzymes with tuned or enhanced reactivity and selectivity towards non-natural substrates.9,10
Fig. 2 Different approaches for artificial metalloenzyme synthesis. The square, circle and pentagons represent organometallic complexes. |
A second approach (II, Fig. 2) has been focused on the creation of a completely new metalloenzyme by insertion strategies of an organometallic complex in a specific area of three-dimensional space within the protein cavity6,9,11,12 with the potential to confer selectivity to chemical reactions or completely new reactivities.13,14 This selectivity would be difficult to achieve using metal catalysts alone.6,9,12,15
The third strategy consists of the replacement of the existing metal ion or organometallic complex inside the natural metalloenzyme with an alternative one (III, Fig. 2), mainly using engineered heme-containing proteins.16,17
The application of these biocatalysts in organic chemistry has been a major challenge in the last few years. In particular, the C–C bond formation represents one of the most useful synthetic tools, since the generation of this bond allows obtaining innumerable “building blocks”, which is a necessary synthetic step in most of the pharmaceutical compounds.18,19 This type of bond can be obtained in several ways. One of the most advantageous ways is the C–H bond activation reaction since it uses molecules not previously activated, which is important for the atom economy and the synthesis process. This is, however, a complex reaction, much more difficult than other C–C bond formations such as cycloaddition, Suzuki–Miyaura or Heck reactions. Therefore, the creation of active and selective artificial metalloenzymes in this C–H functionalization process is a challenge necessary to move towards green chemistry.
This mini-review focuses on describing the few examples that up to now exist in the literature about the creation of artificial metalloenzymes with C–H activation activity.
The Arnold group used directed evolution to improve biocatalysis, in particular creating enzymes for reactions that neither synthetic chemistry nor biology had exploited.10,21 Regarding C–H bond activation, they devoted their effort to engineering iron-containing proteins, making iron a suitable catalyst for these reactions. This strategy consisted of altering the coordination of the iron metal in the catalytic core of the enzyme by modifying the protein amino acids (type I class of metalloenzymes, Fig. 2).21
Thus, a highly enantioselective intramolecular amination of benzylic C–H bonds was obtained using an engineered modified cytochrome P450 monooxygenase (Cytocrome P411CHA).22 Particular mutations were located at the active sites (Fig. 3a) impacting positively the selectivity and activity when compared with another variant that did not have them. This variant showed excellent results in the enantioselective amination of alkane 1 (Fig. 3b) obtaining, under a particular set of conditions, the benzylic amine 2 at >99% enantiomeric excess (ee).
Fig. 3 (a) Active site of the cytochrome P411 mutant (P-4 A82L A78V F263L). The haem group is presented in white and in orange is the iron atom. The key active site residues are shown as sticks in blue and labelled. (b) Cytocrome P411-catalysed C–H amination proposed mechanism. Nitrene transference is achieved thanks to the haem group reduction. Ts: p-toluenesulfonyl; Ser: serine. Figure adapted from ref. 22. |
The mechanism proposed for the intermolecular amination catalyzed by the enzyme consists, first of all, of the reduction of the ferric state of the haem cofactor ((a), Fig. 3b), with electrons derived from NADPH, giving the ferrous state (b). The reaction with tosyl azide (TsN3), a source of nitrene, provides the iron nitrenoid (c) (Fig. 3b). A subsequent reaction of this intermediate with 4-ethylanisole (1) would yield the amination product C–H 2 and regenerate the ferrous state of the catalyst (b).
Indeed, using 10 mM of both substrates (1 and TsN3), P411CHA artificial enzyme can support up to 1300 turnovers, far exceeding the highest turnover number (TON) reported with any chiral transition metal complex for intermolecular enantioselective C–H amination (the best reported is 85 TON using a chiral manganese porphyrin).23
Optimization of the reaction allowed the synthesis of product 2 with a yield of 86%, with >99% ee and 670 turnovers in water at room temperature in contrast to the chemical protocols reported (Fig. 4).
Fig. 4 Substrate range of intramolecular C–H amination catalyzed by cells expressing P411CHA. The figure is adapted from ref. 22. |
Substrate range studies revealed that this artificial metalloenzyme recognized a wide variety of alkanes (Fig. 4), which makes this iron-based catalyst suitable for synthetic chemistry. The enantiomeric excesses for all substrates were excellent in most cases (>95% ee) (Fig. 4). The yields, on the other hand, depended on the substituents and the position in the aromatic ring, e.g. with the methyl substituent at the para or meta position (4a–4b), more than 50% yield was obtained (Fig. 4) while it was less than 15% when the group was at the ortho position (4c).22
The intramolecular activation of C–H produced good overall yields (>70%) (4f–4i) (Fig. 4).
A very recent work by the Arnold group also showed an outstanding application of another version of the evolved cytochrome P450 enzyme (Cytochrome P411CHF) in catalytic enantio-, regio- and chemoselective intermolecular alkylation of sp3 C–H bonds through carbene C–H insertion with high turnover and excellent selectivity (Fig. 5).24
They created more than 70 different haem proteins tested in the C–H alkylation reaction at room temperature and under anaerobic conditions using p-methoxybenzyl methyl ether (5) and ethyl diazoacetate (6) (Fig. 6).24 Product 7 was synthesized using the cytochrome P411CHF variant with an excellent stereoselectivity 96.7:3.3 enantiomeric ratio (er) and 2020 total turnover number (TTN). Even, the enzymatic C–H activation was successfully extended using 1.0 mmol 5, obtaining an isolated product yield of 82%, 1060 TTN, and 98.0:2.0 er.24
Fig. 6 C–H alkylation catalyzed by the P411CHF enzyme variant. (a) Alkylation of 5. (b) Selected examples of synthesized products by this strategy. |
Finally, the authors demonstrated the applicability of this methodology to extend the enzymatic C–H alkylation in different benzylic, allylic, propargylic, alkylamine and diazo compounds, with up to 30 different compounds being successfully synthesized (Fig. 6b).24
C–H alkylation represents a very interesting chemical reaction. In this term, recently, the Fasan group has developed different evolved myoglobin variants for site-specific C–H cyclopropanation25–27 or functionalization of unprotected indoles.28
Functionalized indoles are very interesting molecules which have received significant attention.29 They are structural motifs found in many biologically active molecules.30
Initially, the Fasan group prepared a set of different variants of sperm whale myoglobin (Mb) by amino acid modifications at the active site.28 Then, they performed the first test of C3-functionalization directly on the reaction of an unprotected indole 14 and ethyl α-diazoacetate (6) to synthesize 15 (Fig. 7). They compared the new variants with the native Mb and the best result was found at pH 9, where 85% conversion of a completely C–H activation product was found using the Mb variant (H64V,V68A). The catalytic efficiency of this enzyme was more than 3 times higher than that reported using metal based catalysts for the C3 functionalization of N-protected indoles.31
Fig. 7 C–H functionalization of indole alkylation with ethyl α-diazoacetate catalyzed by the Mb(H64V,V68A) variant. |
However, they obtained a complete conversion in the process by using a whole cell biotransformation, using E. coli cells expressing the Mb(H64V,V68A) variant (Fig. 7). The scope of the reaction was carried out using whole cells as a catalyst using different substituted-indole substrates with excellent results in many cases (Fig. 7).
Engineered variants of cytochrome P45032 or myoglobin33 have also been created for synthetic C–H oxidation processes, with a clear application in the total enantioselective synthesis of the norditerpenoid alkaloid nigelladine A.32
The expansion in the C–H reactivity of the evolved cytochrome P450 has been recently demonstrated in the tunable enantioselective C–H intramolecular amidation reactions of divergently constructed β-, γ- and δ-lactams.34
In this case, directed evolution was used to obtain the LSsp3 variant that catalyzed the amidation reaction of 20 with a TTN (total turnover number) value of >200000 and an enantiomeric excess (ee) of 96% (Fig. 8). The application of this variant to other substrates once again demonstrated the potential of this technique.34
Fig. 8 Synthesis of β-lactams by an enantioselective C–H reaction catalyzed by P411 variants.34 |
In this area, a successful strategy has been developed in recent years by the Ward group, using the biotin-(strept)avidin technology to locate biotinylated metal derivatives within (strept)avidin.6,9,11,35–38 This methodology has allowed the synthesis of different artificial metalloenzymes with very efficient catalytic properties in different reactions such as reduction, oxidation and C–C bond formation.6,35–38
In particular, one of the most successful complex applications of this technology has been the activation of C–H bonds. In this term, the conjugation of streptavidin with biotin site-specifically modified with an organometallic rhodium(III) molecule generated a highly active and selective catalyst for an asymmetric C–H activation (Fig. 9).
Fig. 9 (a) Artificial metalloenzyme preparation. (b) Benzannulation reaction of different substrates catalyzed by the Rh-Bio-Strep biohybrid. |
Interesting results were found depending on the substituent on the aromatic ring in the pivaloyl-protected benzhydroxamic acid (22–24) or on the alkene moiety (25a-d) (Fig. 9b). In particular, isoquinolone 26d was synthesized using this artificial metalloenzyme with a very high enantiopreference and enantioselectivity with >85% enantiomeric excess (ee), showing a 100-fold rate acceleration compared to the isolated Rh(III) complex.38
Following this previous approach, the Rovis group has recently performed the asymmetric synthesis of α,β-unsaturated-δ-lactams by a tandem C–H activation and [4 + 2] annulation reaction using a monomeric streptavidin-Rh(III)-complex hybrid.39
In this case the Rh cyclopentadienyl embedded on monomeric streptavidin, in comparison with the tetrameric protein employed by the previous group, was an excellent catalyst for the preparation of different δ-lactams, via a direct enantioselective coupling of acrylamide hydroxamate esters and styrenes, with an excellent yield (99%) and enantiomeric excess (>96%) under aqueous conditions at room temperature.39
A different approach focused on the creation of an artificial Ru-P450 hybrid for a photocatalytic C–H activation (Fig. 10).40,41
Fig. 10 Representation of a photocatalytic C–H activation by a novel Ru-P450 hybrid enzyme. Reprinted with permission from ref. 41. Copyright 2014 Elsevier. |
A set of different Ru(ii) complexes as photosensitizers were covalently attached near the heme active site of the P450 BM3 enzyme, in order to evaluate the effect of the substituent in photocatalytic applications. The mechanism of action of the new hybrid system is based on the fact that upon light activation, the Ru(II) photosensitizer is quenched by sodium diethyldithiocarbamate (DTC), generating highly reductive species capable of rapidly delivering electrons to the heme active site to initiate the C–H activation reaction.
One of these hybrid catalysts was successfully applied in the C–H activation under visible light by selective monohydroxylation of 10-undecenoic acid (27) producing the enantiomer R-28 in 85% ee. Hydroxylation occurs exclusively at the allylic position (Fig. 10).41
This result opens a future line of research into the generation of hybrid enzymes activated by light for photocatalytic C–C bond reactions.
In this case, the incorporation of the metal by using this strategy could overcome some limitations that could exist in terms of spatial arrangement of the metal complex at the protein active sites in the case of the preparation of artificial metalloproteins from un-natural metalloenzymes.
The methodology has been clearly demonstrated in oxidation reactions, and C–C bond processes46 and, recently, some examples confirmed its applicability in the activation of C–H in water.42–45
The Hartwig group pioneered the development of new artificial enzymes with new reactivities by formally replacing iron in Fe-porphyrin IX (Fe-PIX) proteins with non-biological metals (Fig. 11), with a particular focus on C–H activation enzymes.42–44
Fig. 11 Structure of a cytochrome P450, Fe-CYP119 and its active centre residues. Reprinted with permission from ref. 44. Copyright 2017 American Chemical Society. |
They selected cytochrome P450 enzymes (P450s) that are native metalloproteins containing Fe-protoporphyrin IX (Fe-PIX) as a model for the creation of new reconstituted enzymes. This was a good example because, in principle, the native enzymes could catalyze some C–H oxidation and halogenation47 but not less reactive C–H bond functionalization.
In the process of creating robust artificial metalloenzymes, they designed an artificial reconstituted enzyme from an engineered P450 enzyme variant (CYP119)44 (Fig. 11), which is a thermally stable P450 from the archaeon Sulfolobus solfataricus.
This CYP119 P450 enzyme variant was used for the creation of a reconstituted metalloenzyme in which the heme was exchanged for an iridium porphyrin cofactor (Ir(Me)-PIX) that successfully catalyzed the enantioselective intramolecular C–H bond amination reaction of sulfonyl azides (Fig. 12).43
Initially, the previous artificial enzyme Ir(Me)-PIX CYP119, with the CYP119 variant containing five mutations (C317G, L69V, T213G, V254L, and L155G), showed excellent catalytic performance in the C–H reaction to transform sulfonyl azide 29 in the sulfonamide 30 with a yield of 98% with an enantiomeric ratio of 63:37 (Fig. 12a).43
Different variants of CYP119 were created, in which 3 to 5 amino acids were modified from those mutated at the active sites by means of molecular biology techniques.44 These were used to create new Ir-artificial enzymes. By changing the mutations in the variant, this artificial metalloenzyme showed excellent results in the C–H activation, for example with 29 improving the enantiomeric ratio (84:16) or using different substrates that produce different sulfonamides 31–32, particularly 31 in almost quantitative yields with excellent enantioselectivity (95:5 er) and chemoselectivity (20:1) (Fig. 12b).43
In addition, the preparation of Ir-CYP119 artificial enzymes, where the protein contained three mutations, showed excellent results in the enantioselective C–H amination of aryloxysulfonyl azides 33–34, especially in 33 (with azide instead of an amino group), where >80% yield of product 35 was obtained with a high enantiomeric ratio (90:10) (Fig. 12c). This result represents a challenging C–H amination reaction, because no known enzyme catalyzes the transformation of compound 33 to 35, and forms the product with low yield and enantioselectivity with rhodium catalysts.
Myoglobins are another type of hemoprotein used as a starting point for the creation of artificial metalloenzymes through this reconstitution strategy.42
In this case, the Hartwig group applied a similar strategy discussed earlier in a previous section to create a number of novel artificial enzymes by adding abiological metal complexes such as the metal–porphyrin complexes of Ru, Rh, Ir, Co, Cu, Mn and Ag to apo-PIX-proteins.42 These artificial [M]-myoglobins, which contain various metals and axial ligands, were tested in the C–H functionalization reaction of diazoester 36 to form chiral dihydrobenzofuran 37 (Fig. 13). All native myoglobins (containing iron complex) were completely inactive in the reaction, whereas the new artificial myoglobins containing different metal complexes (Co(Cl), Rh or Ir(Cl), among others) were active catalysts in this C–H activation process.
Fig. 13 Evaluation of the artificial Myo catalysts for the insertion of carbenes into C–H bonds. TON: turnover number. The figure is adapted from ref. 42. |
Differences were also observed with the same metal complex introduced in Myo-H93X, each with a different mutation at the axial ligand position (H93X) (Fig. 13). However, the best catalyst for C–H functionalization was the variant containing Ir(Me)-PIX synthesised incorporating both a non-native metal (Ir) and an axial ligand (–CH3) that cannot be incorporated by standard mutagenesis techniques. In this case, good results were obtained in almost all cases, independently of the mutation at position 93 (50% yield without any mutation) (Fig. 13).
The directed evolution strategy was also used in the enzyme to find the optimal Ir(Me)PIX-Myo artificial enzymes able to perform C–H activation on a variety of substrates.42
After four rounds and more than 20 mutants, the variant containing mutations in 93G, 64L, 43L and 99F (Fig. 14) was the optimal Ir-PIX-Myo enzyme that catalyzed the production of 38 with excellent enantioselectivity, with an enantiomeric ratio of 98:2 (TON of 92)42 instead of the non-selective results using the starting non-evolved enzyme (Fig. 14), demonstrating that the combination of chemical and molecular biological strategies allows the expansion and scope of the most difficult C–H functionalization of these new artificial enzymes.
Fig. 14 Strategy using directed evolution on myoglobin to produce new enantioselective Ir-Myo-mutants. (a) Image of the active site and its surrounding produced in Chimera from PDB 1MBN. (b) Directed evolution (4-rounds) to produce the best final mutant to obtain the most enantioselective artificial enzyme in the synthesis of 38. The figure is adapted from ref. 42. |
The use of genetic tools, especially directed evolution, has allowed the transformation of natural enzymes with specific activity to synthetic enzymes, many of them not existing in Nature. Direct insertion of organometallic complexes into the specific regions of a protein has proved to be a solid technique for performing C–H activation reactions as well as photocatalysis.
In addition, the search for new alternatives in the development of these types of reactions with biohybrids is a safe bet. One of the examples in which biocatalysis has a wide field to explore is the use of Earth-abundant metals such as Fe, Cu, Co or Mn as catalysts in C–H reactions. This can be achieved in some cases by inserting a metallic complex into a protein structure, but research is still needed to expand this field.
The development of methodologies that allow the generation of alternative active sites in specific enzymes, generating enzymatic and metallic activities, has been the key for the success of biocatalysis. Future advances in molecular genetics, protein engineering, bioinformatics or nanotechnology will pave the way for further research. The development of artificial metalloenzymes that combine multiple catalytic activities in a single structure will reduce the steps necessary to obtain a final product. This is really interesting from an economic point of view, due to its possible impact on the chemical or pharmaceutical industries, for example.
This journal is © The Royal Society of Chemistry 2019 |